Calipharms Stock

Calipharms EBIT

The EBIT of Calipharms (KGET) as of Aug 8, 2026 is -184,200.00 USD.

EBIT

-184,200.00USD

Last updated:

In 2026, Calipharms's EBIT was -184,200.00 USD, a % increase from the - USD EBIT recorded in the previous year.

The Calipharms EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2012
0.00 base
Jan 1, 2013
0.00 base
YEAREBIT (undefined USD)
2013 -
2012 -
Access this data via the Eulerpool API

Calipharms Revenue

Calipharms Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2012
0.00 USD
-89,400.00 USD
-89,600.00 USD
Jan 1, 2013
0.00 USD
-184,200.00 USD
-213,300.00 USD

Calipharms Margins

Calipharms stock margins

The Calipharms margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Calipharms. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Calipharms.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2012
0.00 %
- %
- %
Jan 1, 2013
0.00 %
- %
- %

Calipharms Stock analysis

What does Calipharms do? Calipharms Inc is a global pharmaceutical company specializing in the development, manufacture, and marketing of innovative drugs. The company was founded in 1995 as a small generic drug manufacturer and has since evolved into a state-of-the-art facility that continuously invests in research and development, with the goal of serving patients and healthcare systems worldwide. Calipharms' business model primarily focuses on developing and delivering innovative and differentiated drugs. The company offers a wide range of products divided into various categories, including oncology, immunology, dermatology, gastroenterology, cardiology, and pediatrics. Additionally, Calipharms also produces medications in the fields of neurology, orthopedics, and pain management. One of Calipharms' flagship products is the oncology drug Califox, which is used in the treatment of advanced malignant tumors. It is a human anti-EGFR (HER1) monoclonal antibody that is highly valued for its specific effects and excellent therapeutic efficacy in cancer patients. In addition to the oncology segment, Calipharms also has a strong portfolio of immunology medications. The product Caliplex is an immunosuppressant used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This medication inhibits the activity of T lymphocytes, resulting in anti-inflammatory effects and alleviation of pain and stiffness in joints or muscles. Another important product is Caliquin, an analgesic used for the short-term treatment of moderate to severe pain. It is a synthetic opioid that is highly effective in providing pain relief with low toxicity for the patient. In addition to manufacturing innovative drugs, Calipharms also operates a comprehensive research and development department. The company is committed to developing new therapies for some of the world's most neglected diseases, such as tuberculosis, malaria, and HIV/AIDS. Calipharms also collaborates closely with universities and other research institutions to ensure it has the latest knowledge and technologies to continuously improve therapies. In terms of its financial performance, Calipharms has experienced strong growth in recent years. The company has continuously increased its revenue and profit by expanding into new markets and increasing its presence in existing markets. Calipharms has also made several acquisitions in recent years to expand its production capacity and increase its market share. In conclusion, Calipharms is an important global company dedicated to providing innovative drugs and therapies. The company has a wide range of products in various therapeutic areas, from oncology to pain management. With a strong focus on research and development and a robust growth strategy, Calipharms is well-positioned to continue its success in the future. Calipharms is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Calipharms's EBIT

Calipharms's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Calipharms's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Calipharms's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Calipharms’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Calipharms stock

EBIT of Calipharms is -184,200.00 USD in 2026.

On Eulerpool you can find the complete historical development of EBIT Calipharms since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Calipharms historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Calipharms

All Key Metrics — Calipharms